Unknown PHASE4 INTERVENTIONAL 1-arm NCT05418036

Safety Assessment for Sotalol Protocol in Outpatient Unit (Sotalol)

Sponsor: University of Sao Paulo General Hospital

Conditions Antiarrhythmic Drug Adverse Reaction Proarrhythmia Supraventricular Arrhythmia Ventricular Arrythmia

Updated 5 times since 2022 Last updated: Jul 7, 2022 Started: Oct 26, 2020 Primary completion: Feb 28, 2023 Completion: Jun 30, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Antiarrhythmic Drug Adverse Reaction and Proarrhythmia and is currently ongoing. University of Sao Paulo General Hospital leads this study, which shows 5 recorded versions since 2020 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE4
Aug 2024 — Sep 2024 [monthly]

Unknown PHASE4

Status: Recruiting → Unknown
Jul 2024 — Aug 2024 [monthly]

Recruiting PHASE4
Sep 2022 — Jul 2024 [monthly]

Recruiting PHASE4
Jul 2022 — Sep 2022 [monthly]

Recruiting PHASE4

First recorded

Oct 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University of Sao Paulo General Hospital

Data source: University of Sao Paulo General Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• São Paulo, Brazil